DNA
NYSE
$7.55
Ginkgo Bioworks Holdings Inc - Class A (DNA)
Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms suitable for a wide range of sectors, including pharmaceuticals, agriculture, and industrial biotechnology. The company's innovative platform streamlines cellular design and manufacturing, positioning Ginkgo as a key player in addressing critical global challenges such as climate change and food security. With a strong focus on sustainable biotechnology solutions, Ginkgo is well-equipped to tap into the increasing market demand for bio-based alternatives, highlighting its potential for significant growth and transformative impact across various industries.
Sector:
Healthcare
Industry:
Biotechnology
Sell
Target: $8.50 (+12.58%)
Market Cap
$556M
Free Cash Flow Yield
-30.28%
Beta (5Y)
2.33
Price Chart
Valuation
Market Cap$556M
P/S3.81
P/B1.33
Profitability
Total Revenue (TTM)$151M
Gross Profit (TTM)$105M
EBITDA-$249M
Profit Margin-201%
Operating Margin-366.5%
EPS-$5.24
Financial Health
Free Cash Flow Yield-30.28%
Growth & Risk
Revenue 5Y CAGR+4.63%
Beta (5Y)2.33
Sharpe Ratio0.18